Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma - Quiz - MDSpire

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • By

  • Laura B. Oswald

  • Xiaoyin Li

  • Lisa M. Gudenkauf

  • Gabe De Avila

  • David Scheiber-Camoretti

  • Brent J. Small

  • Brian D. Gonzalez

  • Aasha I. Hoogland

  • Oanh Nguyen

  • Yvelise Rodriguez

  • Sylvia L. Crowder

  • Nathan H. Parker

  • Tiffany L. Carson

  • Christine E. Vinci

  • Rachid C. Baz

  • Kenneth H. Shain

  • Brandon Blue

  • Ariel Grajales-Cruz

  • Kristy Matte

  • Brandon Kale

  • David Kaldas

  • Fabiana Perna

  • Melissa Alsina

  • Ciara L. Freeman

  • Omar Castaneda Puglianini

  • Taiga Nishihori

  • Hien Liu

  • Frederick L. Locke

  • Heather S. L. Jim

  • Lauren C. Peres

  • Doris K. Hansen

  • May 11, 2026

  • 0 min

Share

Original Source(s)

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • by Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen

  • May 11, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors